Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Molenbeek-Saint-Jean – page 43

2 121 clinical trials in Molenbeek-Saint-Jean, Belgium. Every trial is listed in the EU Clinical Trials Register and updated daily.

Molenbeek-Saint-Jean at a glance
2 121
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

2 121 trials in Molenbeek-Saint-Jean

Open in trial search

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Vedolizumab, Budesonide, and Prednisone for Children with Moderate to Severe Crohn's Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Budesonide
  • Sponsor:Takeda Development Center Americas Inc.

Study of Linvoseltamab in Adults with Relapsed or Refractory Multiple Myeloma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on F-18 PSMA-11 PET Imaging for Liver Cancer in Patients to Evaluate Survival

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide ALF-18
  • Sponsor:Universitair Ziekenhuis Gent

Psoriasis

Recruiting

Study on Proactive Drug Monitoring with Secukinumab, Ixekizumab, or Guselkumab for Patients with Moderate-to-Severe Psoriasis

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Universitair Ziekenhuis Gent

Myelofibrosis+1

Recruiting

Study on Long-Term Safety of Pelabresib for Patients with Myelofibrosis or Essential Thrombocythemia

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pelabresib monohydrate
  • Sponsor:Novartis Pharma AG

Study Comparing OSE2101 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After Immunotherapy Resistance

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:OSE Immunotherapeutics

Study on the Effects of Mexiletine for Treating Myotonic Dystrophy Types 1 and 2 in Patients

Investigational
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Mexiletine Hydrochloride
  • Sponsor:Lupin Atlantis Holdings S.A.

Long-Term Safety and Efficacy Study of Givinostat for Patients with Duchenne Muscular Dystrophy Previously Treated with Givinostat

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Givinostat
  • Sponsor:Italfarmaco S.p.A.

Study of zongertinib tablets in patients with advanced solid tumors that have HER2 gene changes

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Zongertinib
  • Sponsor:Boehringer Ingelheim Espana S.A.

Study on the Effects of Adding Durvalumab After Chemotherapy and Surgery in Patients with Resectable Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:ETOP IBCSG Partners Foundation

Study of fluorouracil, irinotecan and oxaliplatin combination therapy for patients with metastatic pancreatic ductal adenocarcinoma who progressed after gemcitabine treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Groupe Belge D'Oncologie Digestive

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Molenbeek-Saint-Jean

What the registry says about research in the country

01 Gastroenterology Research

Clinical investigations focusing on proton pump inhibitor (PPI) deprescribing strategies for patients with chronic usage patterns. This research explores alternative treatment approaches for managing functional dyspepsia and related gastrointestinal conditions.

  • PPI Deprescribing Methods
  • Gastrointestinal Health Management
  • Alternative Treatment Strategies

Comparing effectiveness of on-demand medication use and alginate formulation therapy against traditional gradual dose reduction approaches.

02 Primary Care Innovation

Research examining optimal medication management strategies in the primary care setting, particularly focusing on patients with heartburn and reflux symptoms without clear long-term treatment indications.

  • Medication Optimization
  • Patient-Centered Care
  • Chronic Disease Management

Evaluating patient outcomes and treatment success rates across different therapeutic approaches in primary care settings.

03 Therapeutic Alternatives

Investigation into sustainable treatment options for managing gastrointestinal disorders, comparing conventional medication tapering with newer therapeutic strategies.

  • Medication Reduction Strategies
  • Alternative Therapies
  • Long-term Health Outcomes

Assessing the comparative effectiveness of different treatment approaches for chronic digestive conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.